Journal article
Treatment with an interleukin-1 receptor antagonist mitigates neuroinflammation and brain damage after polytrauma
M Sun, RD Brady, DK Wright, HA Kim, SR Zhang, CG Sobey, MR Johnstone, TJ O'Brien, BD Semple, SJ McDonald, SR Shultz
Brain Behavior and Immunity | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2017
Abstract
Traumatic brain injury (TBI) and long bone fracture are common in polytrauma. This injury combination in mice results in elevated levels of the pro-inflammatory cytokine interleukin-1β (IL-1β) and exacerbated neuropathology when compared to isolated-TBI. Here we examined the effect of treatment with an IL-1 receptor antagonist (IL-1ra) in mice given a TBI and a concomitant tibial fracture (i.e., polytrauma). Adult male C57BL/6 mice were given sham-injuries or polytrauma and treated with saline-vehicle or IL-1ra (100 mg/kg). Treatments were subcutaneously injected at 1, 6, and 24 h, and then once daily for one week post-injury. 7–8 mice/group were euthanized at 48 h post-injury. 12–16 mice/gr..
View full abstractGrants
Awarded by St. Jude Medical
Funding Acknowledgements
This work was supported by grants to SRS from the National Health and Medical Research Council (grant number 1062653) and to SJM from La Trobe University (RFA Understanding Disease), as well as fellowships to SRS and BDS from NHMRC. We acknowledge the scientific and technical assistance of the animal MRI facility at the Florey Institute of Neuroscience and Mental Health, a node of the National Imaging Facility.